CMS makes it official, codifying Medicare drug price negotiations established under IRA
The Centers for Medicare and Medicaid Services issued a final rule on November 5, 2026, codifying the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act. The regulation establishes a permanent framework for Initial Price Applicability Year 2029 and subsequent years, detailing drug selection processes, manufacturer requirements, Part D coverage, and biotech protections. The rule locks in permanent procedures for choosing high-spending drugs, negotiating maximum fair prices, guarding against product reformulation strategies, and publishing maximum fair prices. The policy takes effect on December 5, 2026.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The Centers for Medicare and Medicaid Services issued the final rule governing the Inflation Reduction Act's Medicare Drug Price Negotiation Program on November 5, 2026.
- ✓ The final rule applies to Initial Price Applicability Year 2029 and subsequent years.
- ✓ The regulation creates a permanent framework for selecting high-spending drugs, negotiating maximum fair prices, guarding against reformulation strategies, and carrying negotiated prices into Part D coverage and payment.
- ✓ The new rules are set to become effective on December 5, 2026.
What changed
CMS issued a final rule creating a permanent regulatory framework for the Medicare Drug Price Negotiation Program starting in 2029 and beyond.
Live updates
-
CMS Finalizes Permanent Medicare Drug Price Negotiation Rule
The Centers for Medicare and Medicaid Services issued a final rule on November 5, 2026, codifying the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act. The regulation establishes a permanent framework for Initial Price Applicability Year 2029 and subsequent years, detailing drug selection processes, manufacturer requirements, Part D coverage, and biotech protections. The rule locks in permanent procedures for choosing high-spending drugs, negotiating maximum fair prices, guarding against product reformulation strategies, and publishing maximum fair prices. The policy takes effect on December 5, 2026.
Why it matters
The Inflation Reduction Act previously created the negotiation framework, which federal officials are now turning into permanent regulations. Critics warn that these drug price controls threaten medical innovation and could negatively impact cancer patients' time. Meanwhile, individual companies project minimal royalty impacts through 2035 despite the ongoing changes.
What is confirmed
- The Centers for Medicare and Medicaid Services issued the final rule governing the Inflation Reduction Act's Medicare Drug Price Negotiation Program on November 5, 2026.
- The final rule applies to Initial Price Applicability Year 2029 and subsequent years.
- The regulation creates a permanent framework for selecting high-spending drugs, negotiating maximum fair prices, guarding against reformulation strategies, and carrying negotiated prices into Part D coverage and payment.
- The new rules are set to become effective on December 5, 2026.
Still unconfirmed
- Washington's drug price controls threaten medical innovation.
- A Medicare rule could cost cancer patients their time.
- Halozyme Therapeutics projects zero to minimal royalty impact through 2035.
What to watch next
- Implementation of the final rule when it takes effect on December 5, 2026.
- Further industry and legislative reactions regarding the impact on medical innovation and patient care.
confidence 100%Sources used for this update (13)
- www.yahoo.com — Yahoo
- Fierce Pharma — CMS makes it official, codifying Medicare drug price negotiations established under IRA
- TradingView — Halozyme Therapeutics, Inc. (HALO) Projects Zero To Minimal Royalty Impact Through 2035
- RealClearHealth — A Medicare Rule Could Cost Cancer Patients Their Time
- American Hospital Association — CMS finalizes rule to codify Medicare Drug Price Negotiation Program
- Bloomberg Law News — Trump Finalizes Plan for Fourth Medicare Drug Price Negotiations
- The Mountain Press — Washington's drug price controls threaten medical innovation
- unblock.federalregister.gov — Medicare Drug Price Negotiation Program and Medicare ...
- distilinfo.com — CMS Codifies Medicare Price Negotiations - distilinfo.com
- www.cov.com — CMS Issues Final Rule for the IRA Medicare Drug Price ...
- legis1.com — Medicare Finalizes Drug Price Negotiation Rules for 2029
- www.vitallaw.com — PRESCRIPTION DRUGS—FINAL RULES: CMS... | VitalLaw.com
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community